Loading...

We've got a brand new version of Simply Wall St! Try it out

10x Genomics

Nasdaq:TXG
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TXG
Nasdaq
$6B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
TXG Share Price and Events
7 Day Returns
2.8%
NasdaqGS:TXG
4.8%
US Life Sciences
0.7%
US Market
1 Year Returns
-
NasdaqGS:TXG
18.7%
US Life Sciences
13.7%
US Market
TXG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
10x Genomics (TXG) 2.8% 16.8% - - - -
US Life Sciences 4.8% 6.7% 5.4% 18.7% 93.2% 117.8%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • No trading data on TXG.
  • No trading data on TXG.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is 10x Genomics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for 10x Genomics. This is due to cash flow or dividend data being unavailable. The share price is $61.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 10x Genomics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 10x Genomics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:TXG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-5.41
NasdaqGS:TXG Share Price ** NasdaqGS (2019-11-18) in USD $61.34
United States of America Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 33.43x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 10x Genomics.

NasdaqGS:TXG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TXG Share Price ÷ EPS (both in USD)

= 61.34 ÷ -5.41

-11.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 10x Genomics is loss making, we can't compare its value to the US Life Sciences industry average.
  • 10x Genomics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does 10x Genomics's expected growth come at a high price?
Raw Data
NasdaqGS:TXG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
67.2%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.74x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for 10x Genomics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on 10x Genomics's assets?
Raw Data
NasdaqGS:TXG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $4.38
NasdaqGS:TXG Share Price * NasdaqGS (2019-11-18) in USD $61.34
United States of America Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 5.07x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqGS:TXG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TXG Share Price ÷ Book Value per Share (both in USD)

= 61.34 ÷ 4.38

13.99x

* Primary Listing of 10x Genomics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 10x Genomics is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess 10x Genomics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. 10x Genomics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is 10x Genomics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
67.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is 10x Genomics expected to grow at an attractive rate?
  • 10x Genomics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • 10x Genomics's earnings growth is expected to exceed the United States of America market average.
  • 10x Genomics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:TXG Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:TXG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 67.2%
NasdaqGS:TXG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 26.2%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.3%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:TXG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:TXG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 691 141 1
2022-12-31 557 69 1
2021-12-31 456 39 9 3
2020-12-31 342 -53 -40 4
2019-12-31 241 -99 -35 4
2019-11-19
NasdaqGS:TXG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 221 -23 -100
2019-06-30 197 -43 -105
2019-03-31 171 -60 -109
2018-12-31 146 -76 -112
2017-12-31 71 -11 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • 10x Genomics's earnings are expected to grow significantly at over 20% yearly.
  • 10x Genomics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:TXG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from 10x Genomics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TXG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.21 1.21 1.21 1.00
2022-12-31 0.61 0.61 0.61 1.00
2021-12-31 0.09 0.14 0.03 2.00
2020-12-31 -0.39 -0.21 -0.68 4.00
2019-12-31 -0.38 -0.36 -0.40 3.00
2019-11-19
NasdaqGS:TXG Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -5.41
2019-06-30 -7.27
2019-03-31 -7.81
2018-12-31 -8.40
2017-12-31 -1.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if 10x Genomics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess 10x Genomics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
10x Genomics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has 10x Genomics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 10x Genomics's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 10x Genomics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare 10x Genomics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare 10x Genomics's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
10x Genomics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 10x Genomics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TXG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 221.16 -99.64 118.98 68.29
2019-06-30 196.56 -105.38 105.48 57.16
2019-03-31 171.44 -108.93 96.71 52.35
2018-12-31 146.31 -112.49 87.94 47.54
2017-12-31 71.09 -18.76 46.74 32.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if 10x Genomics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if 10x Genomics has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if 10x Genomics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess 10x Genomics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
10x Genomics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is 10x Genomics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 10x Genomics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 10x Genomics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • 10x Genomics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of 10x Genomics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 10x Genomics Company Filings, last reported 1 month ago.

NasdaqGS:TXG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 421.45 29.69 427.44
2019-06-30 15.30 29.66 56.03
2019-03-31 23.26 29.68 65.08
2018-12-31 23.26 29.68 65.08
2017-12-31 45.91 10.56 47.86
  • 10x Genomics's level of debt (7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if 10x Genomics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • 10x Genomics has sufficient cash runway for more than 3 years based on current free cash flow.
  • 10x Genomics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 49.7% each year.
X
Financial health checks
We assess 10x Genomics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 10x Genomics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is 10x Genomics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 10x Genomics dividends. Estimated to be 0% next year.
If you bought $2,000 of 10x Genomics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 10x Genomics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 10x Genomics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:TXG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:TXG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2019-11-19

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 10x Genomics has not reported any payouts.
  • Unable to verify if 10x Genomics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 10x Genomics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 10x Genomics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of 10x Genomics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess 10x Genomics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 10x Genomics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 10x Genomics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of 10x Genomics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Serge Saxonov
COMPENSATION $1,084,275
AGE 42
TENURE AS CEO 7.3 years
CEO Bio

Dr. Serge Saxonov Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at QuantaLife, where he was responsible for building content, driving new applications and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, he was Founding Architect and Director of R&D at 23andMe. Dr. Saxonov serves as a Director at 10X Genomics, Inc. He received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics and biology from Harvard University.

CEO Compensation
  • Insufficient data for Serge to compare compensation growth.
  • Serge's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the 10x Genomics management team in years:

1.6
Average Tenure
44
Average Age
  • The average tenure for the 10x Genomics management team is less than 2 years, this suggests a new team.
Management Team

Serge Saxonov

TITLE
Co-Founder
COMPENSATION
$1M
AGE
42
TENURE
7.3 yrs

Justin McAnear

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
44
TENURE
1.1 yrs

Eric Whitaker

TITLE
General Counsel
COMPENSATION
$875K
AGE
52
TENURE
2.3 yrs

Ben Hindson

TITLE
Co-Founder
AGE
44
TENURE
7.1 yrs

Paul Wyatt

TITLE
Vice President of Operations

Jonathan Schimmel

TITLE
Vice President of Global Support & Sales Operations
TENURE
3.2 yrs

Sam Ropp

TITLE
Senior Vice President of Global Sales
TENURE
0.8 yrs

Jean Philibert

TITLE
Chief People Officer
AGE
59
TENURE
1.6 yrs

Michael Schnall-Levin

TITLE
Senior Vice President of R&D & Founding Scientist
TENURE
0.8 yrs

Alexander Wong

TITLE
Senior Vice President of Product
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the 10x Genomics board of directors in years:

6
Average Tenure
49.5
Average Age
  • The tenure for the 10x Genomics board of directors is about average.
Board of Directors

John Stuelpnagel

TITLE
Chairman
COMPENSATION
$240K
AGE
61
TENURE
6.3 yrs

Serge Saxonov

TITLE
Co-Founder
COMPENSATION
$1M
AGE
42
TENURE
7.3 yrs

Ben Hindson

TITLE
Co-Founder
AGE
44
TENURE
7.3 yrs

Sri Kosaraju

TITLE
Independent Director
AGE
41
TENURE
0.6 yrs

Shehnaaz Suliman

TITLE
Independent Director
AGE
48
TENURE
0.3 yrs

Bryan Roberts

TITLE
Independent Director
AGE
52
TENURE
6 yrs

Paul Conley

TITLE
Independent Director
AGE
51
TENURE
6 yrs

Mathai Mammen

TITLE
Independent Director
AGE
52
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
17. Sep 19 Buy VR Adviser, LLC Company 16. Sep 19 16. Sep 19 300,000 $39.00 $11,700,000
16. Sep 19 Buy Foresite Capital Management, LLC Company 12. Sep 19 12. Sep 19 187,500 $39.00 $7,312,500
X
Management checks
We assess 10x Genomics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 10x Genomics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems. The company serves researchers in approximately 40 countries. Its customers include a range of academic, government, biopharmaceutical, biotechnology, and other institutions worldwide. 10X Genomics, Inc. was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. The company was incorporated in 2012 and is based in Pleasanton, California.

Details
Name: 10x Genomics, Inc.
TXG
Exchange: NasdaqGS
Founded: 2012
$5,899,064,978
96,169,954
Website: http://www.10xgenomics.com
Address: 10x Genomics, Inc.
6230 Stoneridge Mall Road,
Pleasanton,
California, 94588,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TXG Class A Common Stock Nasdaq Global Select US USD 12. Sep 2019
DB 1KJ Class A Common Stock Deutsche Boerse AG DE EUR 12. Sep 2019
BST 1KJ Class A Common Stock Boerse-Stuttgart DE EUR 12. Sep 2019
Number of employees
Current staff
Staff numbers
557
10x Genomics employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/19 01:09
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/08
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.